Pfizer Files Proxy Materials
Ticker: PFE · Form: DEFA14A · Filed: Apr 11, 2024 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | DEFA14A |
| Filed Date | Apr 11, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy, shareholder-meeting, governance
Related Tickers: PFE
TL;DR
Pfizer dropped its proxy statement, get ready to vote!
AI Summary
Pfizer Inc. filed a Definitive Additional Materials proxy statement on April 11, 2024. This filing is related to the company's annual meeting and likely contains information about shareholder proposals, director elections, and executive compensation.
Why It Matters
This filing provides shareholders with crucial information to make informed decisions regarding company governance and voting at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a standard proxy filing, not indicating any unusual financial or operational risks.
Key Players & Entities
- Pfizer Inc. (company) — Registrant
- 0000078003-24-000095 (filing_id) — Accession Number
- 20240411 (date) — Filing Date
FAQ
What type of filing is this?
This is a DEFA14A filing, specifically Definitive Additional Materials for a proxy statement.
Who is the registrant?
The registrant is Pfizer Inc.
When was this filing made?
The filing was made on April 11, 2024.
What is the purpose of a DEFA14A filing?
A DEFA14A filing is a Definitive Proxy Statement, used to solicit shareholder votes on matters such as director elections, executive compensation, and other corporate actions.
Does this filing require a fee?
According to the filing, no fee was required, or the fee was paid previously with preliminary materials.
Filing Stats: 130 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2024-04-11 10:57:34
Filing Documents
- pfe1inv.htm (DEFA14A) — 11KB
- pfeinv1_pagex1.jpg (GRAPHIC) — 184KB
- pfeinv1_pagex2.jpg (GRAPHIC) — 226KB
- pfeinv1_pagex3.jpg (GRAPHIC) — 178KB
- pfeinv1_pagex4.jpg (GRAPHIC) — 184KB
- 0000078003-24-000095.txt ( ) — 1073KB
From the Filing
MEDIA Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party Other Than the Registrant Check the Appropriate Box Preliminary Proxy Statement Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement x Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Pfizer Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of filing fee (Check all boxes that apply) x No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11